BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.38M | 5.33M | 14.13M | 2.66M | 2.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.18M | 43.41M | 49.18M | 30.09M | 23.14M |
| Operating Income | -46.18M | -43.41M | -49.18M | -30.09M | -23.14M |
| Income Before Tax | -42.11M | -38.80M | -44.76M | -28.44M | -22.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.11M | -38.80M | -44.76M | -28.44M | -22.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.11M | -38.80M | -44.76M | -28.44M | -22.06M |
| EBIT | -46.18M | -43.41M | -49.18M | -30.09M | -23.14M |
| EBITDA | -46.11M | -43.32M | -49.11M | -30.02M | -23.08M |
| EPS Basic | -0.53 | -0.49 | -1.03 | -50.36 | -54.23 |
| Normalized Basic EPS | -0.33 | -0.30 | -0.64 | -31.48 | -33.89 |
| EPS Diluted | -0.53 | -0.49 | -1.03 | -50.36 | -54.23 |
| Normalized Diluted EPS | -0.33 | -0.30 | -0.64 | -31.48 | -33.89 |
| Average Basic Shares Outstanding | 80.03M | 79.99M | 43.49M | 564.60K | 406.70K |
| Average Diluted Shares Outstanding | 80.03M | 79.99M | 43.49M | 564.60K | 406.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |